Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint

Controlled Clinical Trials

Volumn 21, Issue 4, 2000, Pages 343-359

  Mick, Rosemarie ^a   Crowley, John J ^b   Carroll, Raymond J ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b USA   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Cytostatic agent; Paired failure times; Phase II trial; Time to progression

Indexed keywords

ANTINEOPLASTIC AGENT; LEFLUNOMIDE;

ARTICLE; BIOTECHNOLOGY; CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOSTASIS; DISEASE COURSE; DRUG EFFICACY; HAZARD; HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; COMPUTER SIMULATION; DISEASE PROGRESSION; MODELS, STATISTICAL; RESEARCH DESIGN; TIME FACTORS;

EID: 0033920380     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00058-1     Document Type: Article

References (36)

1. Herson J. Statistical aspects in the design and analysis of phase II clinical trials. Buyse M.E., Staquet M.J., Sylvester R.J. Cancer Clinical Trials. Methods and Practice:1984;Oxford University Press, Oxford.
2. Leventhal B.G., Wittes R.E. Methods in Clinical Oncology. 1988;Raven Press, New York.
3. Simon R. How large should a phase II trial of a new drug be? Cancer Treatment Rep. 71:1987;1079-1085.
4. Thall P.F., Simon R. Incorporating historical control data in planning phase II clinical trials. Stat Med. 9:1990;215-228.
5. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 10:1989;1-10.
6. Fleming T.R. One-sample multiple testing procedures for phase II clinical trials. Biometrics. 38:1982;143-151.
7. Green S.J., Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med. 11:1992;853-862.
8. Ensign L.G., Gehan E.A., Kamen D.S.et al. An optimal three-stage design for phase II clinical trials. Stat Med. 13:1994;1727-1736.
9. Chen T.T. Optimal three-stage designs for phase II cancer clinical trials. Stat Med. 16:1997;2701-2711.
10. Herndon J.E. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin Trials. 19:1998;440-450.
11. Simon R., Wittes R., Ellenberg S. Randomized phase II clinical trials. Cancer Treatment Rep. 68:1985;1375-1381.
12. Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 275:1996;150-154.
13. Markham M. Challenges associated with evaluating the clinical utility of noncytotoxic pharmaceutical agents in oncology. J Cancer Res Clin Oncol. 123:1997;581-582.
14. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs. Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 4:1998;1079-1086.
15. Twardowski P., Gradishar W.J. Clinical trials of antiangiogenic agents. Curr Opin Oncol. 9:1997;584-589.
16. Pinedo H.M. European drug development and its impact on national activities. The Dutch example Cancer Chemother Pharmacol. 42(suppl):1998;S98-S101.
17. Nelson N.J. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst. 90:1998;960-963.
18. Carlson R. Four MMPIs complete phase I trials, three in phase III. Clin Cancer Lett. December 21:1998;3.
19. Carlson R. Manufacturers skipping phase II trials of MMPIs, plan use as adjuvant therapy. Clin Cancer Lett. December 21:1998;6.
20. Ratain M.J., Mick R., Schilsky R.L.et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 85:1993;1637-1643.
21. Kalbfleisch J.D., Prentice R.L. The Statistical Analysis of Failure Time Data. 1980;John Wiley & Sons, New York.
22. Johnson N.L., Kotz S. Distributions in Statistics. Continuous Multivariate Distributions:1972;Wiley, New York.
23. McWilliams N.B., Hayes F.A., Green A.A.et al. Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma. A Pediatric Oncology Group randomized phase II study Med Pediatr Oncol. 24:1995;176-180.
24. Russell C.A., Green S.J., O'Sullivan J.O.et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer. A Southwest Oncology Group phase III trial J Clin Oncol. 15:1999;2494-2501.
25. Canellos G., Petroni P., Barcos M.et al. Etoposide, vinblastine and doxorubicin. An active regimen for the treatment of Hodgkin's disease in relapse following MOPP J Clin Oncol. 13:1995;2005-2011.
26. Eckhardt S., Rizzo J., Sweeney K.et al. Phase I and pharmacologic study of the tryosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol. 17:1999;1095-1104.
27. Eisenhauer E. Phase I and II trials of novel anticancer agents. Endpoints, efficacy, and existentialism Ann Oncol. 9:1998;1047-1052.
28. George S.L. The required size and length of a phase III clinical trial. Buyse M.E., Staquet M.J., Sylvester R.J. Cancer Clinical Trials. Methods and Practice:1984;Oxford University Press, Oxford.
29. Dixon D.O., Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 41:1988;1209-1214.
30. Ratain M. Development of target-based antineoplastic agents. Proceedings of the American Society of Clinical Oncology; 1999, May 15-18; Atlanta, GA. Baltimore, Williams and Wilkins; 1999. pp 71-75.
31. Kopec J., Abrahamowicz M., Esdaile J. Randomized discontinuation trials. Utility and efficiency J Clin Epidemiol. 46:1993;959-971.
32. Woolson R., Lachenbruch P. Rank tests for censored matched pairs. Biometrika. 67:1980;597-606.
33. O'Brien P., Fleming T. A paired Prentice-Wilcoxon test for censored paired data. Biometrics. 43:1987;169-180.
34. Lee W, Wei LJ, Amato D. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Survival Analysis: State of the Art. Dordrecht: Kluwer; 1992.
35. Jung S.H. Rank tests for matched survival data. Lifetime Data Anal. 5:1999;67-79.
36. Bonetti A, Zaninelli M, Leone R, et al. The use of the growth modulation index to evaluate the activity of oxaliplatin added to a 5FU-based regimen in fluoropyrimidine-resistant colorectal cancer. Proceedings of the AACR, NCI, EORTC International Conference Molecular Targets and Cancer Therapeutics; 1999, November 16-19; Washington, DC. Richmond, American Association for Cancer Research; 1999. p 46.